A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin

Thrombosis Research

Volumn 128, Issue 4, 2011, Pages 361-367

  Jeske, Walter P ^a   Hoppensteadt, Debra ^a   Gray, Angel ^a   Walenga, Jeanine M ^a   Cunanan, Josephine ^a   Myers, Lauren ^a   Fareed, Jawed ^a   Bayol, Alain ^b   Rigal, Hélène ^b   Viskov, Christian ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b SANOFI   (France)

Author keywords

Antithrombotic; Potency; Standardization; Ultra low molecular weight heparin

Indexed keywords

BEMIPARIN; SEMULOPARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BLOOD SAMPLING; CLINICAL ASSESSMENT; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HEPARIN INDUCED THROMBOCYTOPENIA; MOLECULAR WEIGHT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

AUTOANTIBODIES; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION; PLATELET FACTOR 4; PLATELET FUNCTION TESTS; PROTHROMBIN; REFERENCE STANDARDS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN; WHOLE BLOOD COAGULATION TIME;

EID: 80054929642     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.03.001     Document Type: Article

References (23)

1. B. Casu, and G. Torri Structural characterization of low molecular weight heparins Semin Thromb Hemost 25 Suppl 3 1999 17 25 (Pubitemid 29517029)
2. J.M. Walenga, M. Petitou, M. Samama, J. Fareed, and J. Choay Importance of a 3-O-sulfate in a heparin pentasaccharide for antithrombotic activity Thromb Res 52 6 1988 553 563 (Pubitemid 19028227)
3. J. Hirsh, and R. Raschke Heparin and low-molecular-weight heparin Chest 126 2004 188S 203S
4. S. Alban Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma Semin Thromb Hemost 27 5 2001 503 511 (Pubitemid 32989375)
5. E. Holmer, K. Kurachi, and G. Soderstrom The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin Biochem J 193 2 1981 395 400 (Pubitemid 11141360)
6. A.A. Khorana, A. Sahni, O.D. Altland, and C.W. Francis Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight Arterioscler Thromb Vasc Biol 23 2003 2110 2115 (Pubitemid 37433208)
7. B. Bray, D.A. Lane, J.M. Freyssinet, G. Pejler, and U. Lindahl Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin Biochem J 262 1989 225 232 (Pubitemid 19220953)
8. W.P. Jeske, J.M. Walenga, and J. Fareed Differentiating between the low molecular-weight heparins used for venous thromboembolism treatment and prophylaxis G. Merli, Thrombosis Clinic 2(3) 2008 Excerpta Medica/Elsevier Bridgewater, NJ 8 21
9. R.C. Becker New thrombolytic, anticoagulants and platelet antagonists: the future of clinical practice J Thromb Thrombolysis 7 1999 195 220 (Pubitemid 29225001)
10. E.M. Antman, C.H. McCabe, E.P. Gurfinkel, A.G. Turpie, P.J. Bernink, and D. Salein Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial Circulation 100 1999 1593 1601 (Pubitemid 29477267)
11. M. Cohen, C. Demers, E.P. Gurfinkel, A.G. Turpie, G.J. Frommell, and S. Goodman A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease N Engl J Med 337 1997 447 452 (Pubitemid 27333045)
12. T.M. Chapman, and K.L. Goa Bemiparin: A review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis Drugs 63 21 2003 2357 2377 (Pubitemid 37330536)
13. R. Ferriols-Lisart, F. Ferriols-Lisart, and V. Jimenez-Torres Effectiveness and safety of bemiparin versus low molecular weight heparins in orthopaedic surgery Pharm World Sci 24 3 2004 87 94 (Pubitemid 34754761)
14. J. Martinez-Gonzalez, L. Vila, and C. Rodriguez Bemiparin: Second generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism Exp Rev Cardiovasc Ther 6 6 2008 793 802
15. M.R. Lassen, O.E. Dahl, P. Mismetti, D. Destree, and A.G.G. Turpie AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery - TREK: a dose-ranging study J Thromb Haemost 7 4 2009 566 572
16. A. Planes Review of bemiparin sodium - a new second-generation low molecular weight heparin and its applications in venous thromboembolism Exp Opin Pharmacother 4 9 2003 1551 1561 (Pubitemid 37120901)
17. J. Fareed, D. Hoppensteadt, J. Walenga, O. Iqbal, M. Qing, and W. Jeske Pharmacodynamic and pharmacokinetic properties of enoxaparin. Implications for clinical practice Clin Pharmacokinet 42 12 2003 1043 1057 (Pubitemid 37186676)
18. L. Falkon, D. Saenz-Campos, and R. Antonijoan Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11) - a three way cross-over study in healthy volunteers Thromb Res 78 1 1995 77 86
19. C. Viskov, M. Just, V. Laux, P. Mourier, and M. Lorenz Description of the chemical and pharmacologic characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026 J Thromb Haemost 7 2009 1143 1151
20. P.G. Gottschalk, and J.R. Dunn Measuring parallelism, linearity and relative potency in bioassay and immunoassay data J Biopharm Stat 3 2005 437 463 (Pubitemid 40677513)
21. P.G. Gottschalk, and J.R. Dunn The five parameter logistic: a characterization and comparison with the four-parameter logistic Anal Biochem 343 2005 54 65 (Pubitemid 40978609)
22. M.K. Orcullo Santillan, J. Herring, D. Hoppensteadt, W. Jeske, J.M. Herbert, and J. Fareed The effect of a novel glycoprotein IIb/IIIa antagonist, SR 121566A, on platelet aggregation and activation in rhesus monkeys Clin Appl Thromb Hemost 7 1 2001 10 15 (Pubitemid 32112595)
23. M.M. Prechel, and J.M. Walenga The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update Semin Thromb Hemost 34 1 2008 86 96 (Pubitemid 351640884)